{"hands_on_practices": [{"introduction": "A screening test's utility is not just defined by its intrinsic accuracy, but by how its results should be interpreted in a real-world population. This exercise provides a foundational hands-on opportunity to calculate the Positive and Negative Predictive Values ($PPV$ and $NPV$), two of the most critical metrics in clinical practice. By working through this scenario [@problem_id:5074413], you will see how a test's sensitivity and specificity interact with the prevalence of a condition to determine the true probability of disease, a concept that is central to patient counseling.", "problem": "A prenatal genetic screening program for trisomy $21$ is applied to a population in which the prior probability (prevalence) of carrying a fetus with trisomy $21$ is $\\pi = 0.005$. The screening assay has sensitivity $\\text{sens} = 0.90$ and specificity $\\text{spec} = 0.95$. Using only the core definitions of sensitivity, specificity, prevalence, conditional probability, and the law of total probability, compute the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV) for this test in this population. Report both values as decimals (not percentages), rounded to $4$ significant figures. Then, briefly interpret what these values imply for post-test counseling and the role of confirmatory diagnostic testing such as chorionic villus sampling (CVS) or amniocentesis.", "solution": "The problem statement is a valid application of probability theory to the field of medical diagnostics. It is scientifically grounded, self-contained, and well-posed, providing all necessary parameters ($\\pi$, sens, spec) to compute the required values (PPV, NPV) using standard, explicitly named mathematical principles.\n\nLet us define the events as follows:\n- $D$: The event that the fetus has trisomy $21$.\n- $D^c$: The event that the fetus does not have trisomy $21$.\n- $T^+$: The event that the screening test result is positive.\n- $T^-$: The event that the screening test result is negative.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The prior probability, or prevalence, of the condition: $P(D) = \\pi = 0.005$.\n2.  The sensitivity of the test, which is the conditional probability of a positive test given the presence of the disease: $P(T^+ | D) = \\text{sens} = 0.90$.\n3.  The specificity of the test, which is the conditional probability of a negative test given the absence of the disease: $P(T^- | D^c) = \\text{spec} = 0.95$.\n\nFrom these given values, we can deduce other necessary probabilities:\n- The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.005 = 0.995$.\n- The false negative rate, which is the probability of a negative test given the disease is present: $P(T^- | D) = 1 - P(T^+ | D) = 1 - \\text{sens} = 1 - 0.90 = 0.10$.\n- The false positive rate, which is the probability of a positive test given the disease is absent: $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - \\text{spec} = 1 - 0.95 = 0.05$.\n\nOur objective is to compute the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV).\n\n**1. Calculation of the Positive Predictive Value (PPV)**\n\nThe PPV is the conditional probability that a subject has the disease given a positive test result, i.e., $P(D | T^+)$. Using the definition of conditional probability (which is the core of Bayes' theorem):\n$$PPV = P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$$\nThe numerator, $P(D \\cap T^+)$, is the joint probability of having the disease and testing positive. It can be found using the definition of conditional probability:\n$$P(D \\cap T^+) = P(T^+ | D) P(D) = \\text{sens} \\times \\pi$$\nThe denominator, $P(T^+)$, is the total probability of a positive test. It can be found using the law of total probability, considering the two mutually exclusive scenarios: having the disease or not having the disease.\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\n$$P(T^+) = (\\text{sens} \\times \\pi) + ((1 - \\text{spec}) \\times (1 - \\pi))$$\nCombining these, the formula for PPV is:\n$$PPV = \\frac{\\text{sens} \\times \\pi}{(\\text{sens} \\times \\pi) + ((1 - \\text{spec}) \\times (1 - \\pi))}$$\nSubstituting the given numerical values:\n$$PPV = \\frac{0.90 \\times 0.005}{(0.90 \\times 0.005) + (0.05 \\times 0.995)}$$\n$$PPV = \\frac{0.0045}{0.0045 + 0.04975} = \\frac{0.0045}{0.05425} \\approx 0.082949308...$$\nRounding to $4$ significant figures, we get $PPV = 0.08295$.\n\n**2. Calculation of the Negative Predictive Value (NPV)**\n\nThe NPV is the conditional probability that a subject does not have the disease given a negative test result, i.e., $P(D^c | T^-)$. Using the definition of conditional probability:\n$$NPV = P(D^c | T^-) = \\frac{P(D^c \\cap T^-)}{P(T^-)}$$\nThe numerator, $P(D^c \\cap T^-)$, is the joint probability of not having the disease and testing negative:\n$$P(D^c \\cap T^-) = P(T^- | D^c) P(D^c) = \\text{spec} \\times (1 - \\pi)$$\nThe denominator, $P(T^-)$, is the total probability of a negative test. Using the law of total probability:\n$$P(T^-) = P(T^- | D^c) P(D^c) + P(T^- | D) P(D)$$\n$$P(T^-) = (\\text{spec} \\times (1 - \\pi)) + ((1 - \\text{sens}) \\times \\pi)$$\nCombining these, the formula for NPV is:\n$$NPV = \\frac{\\text{spec} \\times (1 - \\pi)}{(\\text{spec} \\times (1 - \\pi)) + ((1 - \\text{sens}) \\times \\pi)}$$\nSubstituting the given numerical values:\n$$NPV = \\frac{0.95 \\times 0.995}{(0.95 \\times 0.995) + (0.10 \\times 0.005)}$$\n$$NPV = \\frac{0.94525}{0.94525 + 0.0005} = \\frac{0.94525}{0.94575} \\approx 0.9994713...$$\nRounding to $4$ significant figures, we get $NPV = 0.9995$.\n\n**3. Interpretation and Implications**\n\nThe calculated $PPV$ of approximately $0.083$ signifies that for a patient who receives a positive screening result, there is only an $8.3\\%$ probability that the fetus actually has trisomy $21$. Conversely, there is a $91.7\\%$ probability that the result is a false positive. This starkly illustrates that a positive screening test is not a diagnosis. For post-test counseling, it is critical to explain that the test identifies an individual as being at higher risk, but the absolute risk may still be low. This result mandates the use of a confirmatory diagnostic test, such as chorionic villus sampling (CVS) or amniocentesis, which are far more accurate but carry a small procedural risk. Screening's role is to stratify the population to determine who should be offered these invasive but definitive tests.\n\nThe calculated $NPV$ of approximately $0.9995$ is extremely high. This means that for a patient who receives a negative test result, there is a $99.95\\%$ probability that the fetus does not have trisomy $21$. A negative result is therefore highly reassuring, effectively ruling out the condition for the vast majority of those screened. The residual risk of having an affected fetus despite a negative screen (a false negative) is very low, approximately $1 - 0.9995 = 0.0005$, or $1$ in $2000$. For this reason, no further testing for trisomy $21$ is typically recommended after a negative screening result.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.08295 & 0.9995\n\\end{pmatrix}\n}\n$$", "id": "5074413"}, {"introduction": "Prenatal screening rarely provides a simple 'yes' or 'no' answer; instead, it refines an individual’s risk. This practice problem demonstrates the powerful method used to update a pre-test risk (like one based on maternal age) using evidence from screening markers, summarized by a Likelihood Ratio ($LR$). Working through this calculation [@problem_id:5074441] will give you hands-on experience with the Bayesian logic at the heart of modern risk assessment, converting abstract probabilities into the concrete risk figures used in clinical counseling.", "problem": "A pregnant person aged $35$ years undergoes first-trimester combined screening for trisomy $21$ based on ultrasound markers and serum analytes. For individuals aged $35$ years, the commonly used maternal-age-specific baseline risk at term for trisomy $21$ is $1$ in $300$. The specific screening result for this individual yields a likelihood ratio of $5$ for trisomy $21$ relative to unaffected pregnancies. \n\nUsing only fundamental definitions of probability, odds, and the likelihood ratio, derive the posterior probability of trisomy $21$ for this individual after the screening result. Then convert this posterior probability into a risk expressed as “$1$ in $N$.” Report:\n- the posterior probability as a decimal (not a percentage), rounded to four significant figures, and\n- the corresponding $N$ (the denominator in “$1$ in $N$”), rounded to two significant figures.\n\nAssume the maternal-age risk is the appropriate pretest probability for the gestational age at which screening was performed, and assume that the likelihood ratio applies to this pretest risk in the target population.", "solution": "The problem is well-posed and scientifically grounded, providing all necessary information to calculate the posterior probability of trisomy $21$ using standard principles of Bayesian inference as applied in medical diagnostics. We shall proceed with a formal derivation.\n\nLet $D$ be the event that the fetus has trisomy $21$. Let $T$ be the specific screening test result obtained for the individual. We are given the following information:\n1.  The prior probability of trisomy $21$, based on maternal age, is given as a risk of $1$ in $300$. We denote this as $P_{prior}(D)$.\n    $$P_{prior}(D) = \\frac{1}{300}$$\n2.  The likelihood ratio ($LR$) associated with the test result $T$ is given as $5$. The likelihood ratio is defined as the probability of the test result in an individual with the condition divided by the probability of the test result in an individual without the condition.\n    $$LR = \\frac{P(T|D)}{P(T|D^c)} = 5$$\n    where $D^c$ is the complement of $D$, representing an unaffected pregnancy.\n\nThe problem requires us to derive the posterior probability, $P_{post}(D) = P(D|T)$, using fundamental definitions. The most direct method involves converting probabilities to odds, updating the odds using the likelihood ratio, and then converting the resulting posterior odds back to a probability.\n\nFirst, we define the odds of an event $A$ as the ratio of the probability of the event occurring to the probability of the event not occurring:\n$$O(A) = \\frac{P(A)}{1 - P(A)}$$\n\nUsing this definition, we calculate the prior odds of trisomy $21$, $O_{prior}(D)$, from the prior probability $P_{prior}(D)$.\nThe probability of an unaffected pregnancy is $P_{prior}(D^c) = 1 - P_{prior}(D) = 1 - \\frac{1}{300} = \\frac{299}{300}$.\nThe prior odds are therefore:\n$$O_{prior}(D) = \\frac{P_{prior}(D)}{P_{prior}(D^c)} = \\frac{1/300}{299/300} = \\frac{1}{299}$$\n\nThe core of Bayesian updating in this context is the relationship:\n$$O_{post} = O_{prior} \\times LR$$\nThis relationship is derived directly from Bayes' theorem. The posterior odds, $O_{post}(D)$, are the odds of having the condition after receiving the test result $T$.\n$$O_{post}(D) = \\frac{P(D|T)}{P(D^c|T)}$$\nBy Bayes' theorem, $P(D|T) = \\frac{P(T|D)P(D)}{P(T)}$ and $P(D^c|T) = \\frac{P(T|D^c)P(D^c)}{P(T)}$.\nSubstituting these into the odds ratio gives:\n$$O_{post}(D) = \\frac{P(T|D)P(D)/P(T)}{P(T|D^c)P(D^c)/P(T)} = \\left(\\frac{P(D)}{P(D^c)}\\right) \\times \\left(\\frac{P(T|D)}{P(T|D^c)}\\right) = O_{prior}(D) \\times LR$$\n\nNow, we can calculate the posterior odds for this individual:\n$$O_{post}(D) = O_{prior}(D) \\times LR = \\frac{1}{299} \\times 5 = \\frac{5}{299}$$\n\nNext, we must convert these posterior odds back into a posterior probability. The relationship to convert odds $O(A)$ to probability $P(A)$ is:\n$$P(A) = \\frac{O(A)}{1 + O(A)}$$\nApplying this to our posterior odds:\n$$P_{post}(D) = \\frac{O_{post}(D)}{1 + O_{post}(D)} = \\frac{5/299}{1 + 5/299} = \\frac{5/299}{(299+5)/299} = \\frac{5}{304}$$\n\nThe problem requires this posterior probability to be expressed as a decimal rounded to four significant figures.\n$$P_{post}(D) = \\frac{5}{304} \\approx 0.016447368...$$\nThe first four significant figures are $1$, $6$, $4$, $4$. The fifth significant figure is $7$, which is $\\ge 5$, so we round up the fourth digit.\n$$P_{post}(D) \\approx 0.01645$$\n\nFinally, we need to convert this posterior probability into a risk expressed in the format \"$1$ in $N$\". This means we set the probability equal to $\\frac{1}{N}$ and solve for $N$.\n$$P_{post}(D) = \\frac{1}{N}$$\n$$N = \\frac{1}{P_{post}(D)} = \\frac{1}{5/304} = \\frac{304}{5} = 60.8$$\nThe problem requires $N$ to be rounded to two significant figures. The first two significant figures of $60.8$ are $6$ and $0$. The next digit is $8$, which is $\\ge 5$, so we round up the second digit.\n$$N \\approx 61$$\n\nThe resulting risk is approximately $1$ in $61$.\n\nThe two values to be reported are the posterior probability rounded to four significant figures and the value of $N$ rounded to two significant figures.\nPosterior probability: $0.01645$\n$N$: $61$", "answer": "$$\\boxed{\\begin{pmatrix} 0.01645 & 61 \\end{pmatrix}}$$", "id": "5074441"}, {"introduction": "Effective clinical practice requires integrating statistical results with biological principles and other clinical data, especially when faced with conflicting information. This case-based problem [@problem_id:5074419] presents a realistic scenario where a low-risk screening result is challenged by abnormal ultrasound findings, pushing you to think critically about the fundamental limitations of cfDNA screening. By reasoning through this challenge, you will learn to appreciate why different tests are needed for different genetic questions and how to formulate a logical diagnostic plan for complex structural chromosome abnormalities.", "problem": "A pregnant individual at gestational age $20$ weeks presents for evaluation after a previously low-risk cell-free deoxyribonucleic acid (cfDNA) screen for trisomy $21$, trisomy $18$, and trisomy $13$ at $11$ weeks with a reported fetal fraction of $f=0.08$ ($8\\%$). The current detailed ultrasound shows growth restriction, a ventricular septal defect, and bilateral cleft lip and palate. There is no known teratogen exposure. A sibling pregnancy ended in second-trimester loss of unknown etiology. The clinical team is concerned about a structural chromosomal disorder, including the possibility of an unbalanced translocation.\n\nUsing fundamental principles of how cfDNA screening operates and the biological basis of chromosomal rearrangements, explain why cfDNA may not reliably detect balanced rearrangements, and determine the most appropriate next diagnostic steps when ultrasound findings raise concern for an unbalanced translocation.\n\nBase your reasoning on the following well-tested facts and definitions:\n- In cfDNA screening, short deoxyribonucleic acid fragments primarily derived from placental trophoblasts are analyzed in maternal plasma; the assay infers fetal copy-number changes by comparing observed read-count proportions per chromosome to expected proportions for a euploid reference.\n- A balanced rearrangement is copy-number neutral at the whole-chromosome and segmental dosage level (no net gain or loss of deoxyribonucleic acid), whereas an unbalanced translocation leads to partial trisomy and/or partial monosomy.\n- Karyotype can visualize structural chromosomal rearrangements at the metaphase level; chromosomal microarray analysis (CMA) detects copy-number variants but does not report balanced events; fluorescence in situ hybridization (FISH) can target specific loci or rearrangements; chorionic villus sampling (CVS) and amniocentesis are invasive diagnostic procedures that obtain fetal cells for direct analysis.\n\nWhich option best captures the limitation of cfDNA for balanced rearrangements and outlines an evidence-based diagnostic strategy when ultrasound markers suggest an unbalanced translocation?\n\nA. cfDNA quantifies relative chromosomal dosage in maternal plasma; balanced rearrangements are copy-number neutral at the chromosomal level, so no change in read-count proportions is expected. When ultrasound suggests an unbalanced translocation, proceed with amniocentesis for fetal karyotype and chromosomal microarray analysis, followed by parental karyotyping and targeted fluorescence in situ hybridization if indicated.\n\nB. cfDNA can detect balanced rearrangements because breakpoints create unique junction sequences; therefore, repeating a higher-depth cfDNA test is the preferred diagnostic approach when ultrasound is abnormal.\n\nC. A microdeletion and microduplication cfDNA panel is diagnostic for unbalanced translocations, obviating the need for invasive testing when ultrasound markers are present.\n\nD. Chromosomal microarray analysis on amniotic fluid suffices in suspected translocation; parental studies are not needed if microarray identifies a copy-number variant.\n\nE. Chorionic villus sampling cannot identify translocations and is contraindicated when a structural chromosomal abnormality is suspected.", "solution": "The validity of the problem statement must first be assessed.\n\n**Step 1: Extract Givens**\n- **Patient Information:** A pregnant individual at gestational age $20$ weeks.\n- **Screening History:** A cell-free deoxyribonucleic acid (cfDNA) screen was performed at $11$ weeks for trisomy $21$, trisomy $18$, and trisomy $13$. The result was low-risk. The reported fetal fraction was $f=0.08$ ($8\\%$).\n- **Ultrasound Findings:** A detailed ultrasound at $20$ weeks reveals growth restriction, a ventricular septal defect, and bilateral cleft lip and palate.\n- **Medical History:** No known teratogen exposure. A prior sibling pregnancy resulted in a second-trimester loss of unknown etiology.\n- **Clinical Concern:** Suspicion of a structural chromosomal disorder, specifically a possible unbalanced translocation.\n- **Question:** Explain why cfDNA may not reliably detect balanced rearrangements and determine the most appropriate next diagnostic steps given the ultrasound findings.\n- **Provided Definitions and Facts:**\n    1.  cfDNA screening analyzes short DNA fragments from placental trophoblasts in maternal plasma and infers fetal copy-number changes by comparing observed read-count proportions per chromosome to a euploid reference.\n    2.  A balanced rearrangement is copy-number neutral (no net gain or loss of DNA).\n    3.  An unbalanced translocation results in partial trisomy and/or partial monosomy.\n    4.  Karyotype visualizes structural chromosomal rearrangements.\n    5.  Chromosomal microarray analysis (CMA) detects copy-number variants but does not report balanced events.\n    6.  Fluorescence in situ hybridization (FISH) targets specific loci or rearrangements.\n    7.  Chorionic villus sampling (CVS) and amniocentesis are invasive diagnostic procedures that obtain fetal cells.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is based on established principles of clinical genetics, cytogenetics, and molecular diagnostics. The scenario presented (low-risk cfDNA screen with subsequent abnormal ultrasound findings) is a recognized clinical challenge. The definitions of the genetic tests and chromosomal abnormalities are accurate.\n- **Well-Posed:** The problem provides a clear clinical context and asks for a specific explanation and a recommendation for a diagnostic strategy, both of which can be derived from the provided facts and fundamental principles. A logical and unique answer exists.\n- **Objective:** The problem is stated using precise, unbiased clinical and scientific language. It is free of subjective claims.\n\n**Verdict:** The problem statement is valid, scientifically sound, and well-posed. It presents a realistic clinical scenario that requires a logical application of the principles of prenatal genetic testing.\n\n**Derivation and Analysis**\n\nThe problem has two parts: explaining the limitation of cfDNA for balanced rearrangements and determining the subsequent diagnostic strategy for a suspected unbalanced translocation.\n\n**Part 1: Limitation of cfDNA for Balanced Rearrangements**\nStandard cfDNA screening is a quantitative method. It operates by sequencing millions of short DNA fragments in maternal plasma and mapping them to their chromosome of origin. The fundamental measurement is the proportion of sequence reads that map to each chromosome. For example, the fraction of reads mapping to chromosome $21$ is calculated and compared to an expected baseline from euploid (chromosomally normal) pregnancies. An increase in this fraction suggests an extra copy of chromosome $21$ (trisomy $21$).\n\nA balanced rearrangement, such as a balanced reciprocal translocation, involves the exchange of genetic material between two or more chromosomes without any net gain or loss of DNA. For instance, if a segment of chromosome $A$ and a segment of chromosome $B$ are exchanged, the total amount of chromosome $A$-specific DNA and chromosome $B$-specific DNA in the genome remains the same. Since the cfDNA analysis relies on counting the total number of fragments per chromosome to assess dosage, and since a balanced rearrangement is by definition copy-number neutral, there is no change in the overall proportion of reads mapping to the involved chromosomes. Therefore, standard cfDNA screening cannot detect balanced rearrangements.\n\n**Part 2: Diagnostic Strategy for Suspected Unbalanced Translocation**\nThe patient presents at $20$ weeks with significant structural anomalies on ultrasound (growth restriction, cardiac defect, clefting) despite a low-risk cfDNA screen. This clinical picture is highly suggestive of a genetic syndrome that was not detected by the initial screen. The cfDNA screen was limited to whole-chromosome aneuploidies for chromosomes $13$, $18$, and $21$. An unbalanced translocation would cause partial monosomy for one chromosomal region and partial trisomy for another. These sub-chromosomal copy number variations are typically not detected by basic cfDNA screening.\n\nGiven the high suspicion for a chromosomal abnormality based on ultrasound, a diagnostic test is required. Screening tests like cfDNA are no longer sufficient. Diagnostic testing requires obtaining a fetal sample through an invasive procedure.\n- **Procedure:** At $20$ weeks gestation, **amniocentesis** is the standard procedure to obtain fetal cells (amniocytes) from the amniotic fluid.\n- **Analysis:** The fetal cells must be analyzed to identify both copy number changes and the underlying structural rearrangement.\n    - **Chromosomal Microarray Analysis (CMA):** This is the first-line test for a fetus with ultrasound anomalies. It excels at detecting sub-microscopic gains and losses of genetic material (copy number variants, or CNVs) with high resolution. It will identify the partial trisomy and partial monosomy characteristic of an unbalanced translocation.\n    - **Karyotype:** This analysis visualizes the chromosomes under a microscope. While CMA identifies the gain and loss of material, a karyotype is necessary to determine the structure of the rearrangement (e.g., to confirm that the CNVs are due to a translocation and to identify the involved chromosomes).\n- **Parental Studies:** The history of a prior pregnancy loss raises the possibility that one parent is a carrier of a balanced translocation. A phenotypically normal individual with a balanced translocation can produce unbalanced gametes, leading to miscarriage, stillbirth, or a child with congenital anomalies. Therefore, if an unbalanced translocation is identified in the fetus, **parental karyotyping** is essential to determine if the rearrangement is inherited or de novo. This information is crucial for counseling regarding recurrence risk in future pregnancies.\n- **Fluorescence In Situ Hybridization (FISH):** This is a targeted test. It could be used for rapid preliminary results on the amniotic fluid (e.g., to count specific chromosomes) or on parental samples to confirm a specific rearrangement identified in the fetus. Its inclusion as a potential follow-up tool (\"if indicated\") is appropriate.\n\nTherefore, the most appropriate diagnostic strategy is amniocentesis for both CMA and fetal karyotype, followed by parental karyotyping if a structural rearrangement is found.\n\n**Option-by-Option Analysis**\n\n**A. cfDNA quantifies relative chromosomal dosage in maternal plasma; balanced rearrangements are copy-number neutral at the chromosomal level, so no change in read-count proportions is expected. When ultrasound suggests an unbalanced translocation, proceed with amniocentesis for fetal karyotype and chromosomal microarray analysis, followed by parental karyotyping and targeted fluorescence in situ hybridization if indicated.**\n- **Evaluation:** This option correctly explains the limitation of cfDNA based on its quantitative nature and the copy-number neutral state of balanced rearrangements. The proposed diagnostic pathway—amniocentesis followed by both CMA and karyotype on the fetal sample, with subsequent parental studies—is the comprehensive, evidence-based standard of care in this clinical scenario.\n- **Verdict:** **Correct**.\n\n**B. cfDNA can detect balanced rearrangements because breakpoints create unique junction sequences; therefore, repeating a higher-depth cfDNA test is the preferred diagnostic approach when ultrasound is abnormal.**\n- **Evaluation:** This statement is fundamentally incorrect. Standard cfDNA screening does not analyze breakpoint junctions; it is a dosage-counting method. Research into using whole-genome sequencing on cfDNA to find such junctions exists, but it is not the basis of the defined screening test. Furthermore, repeating a screening test in the face of definitive ultrasound anomalies is clinically inappropriate; a diagnostic test is mandated.\n- **Verdict:** **Incorrect**.\n\n**C. A microdeletion and microduplication cfDNA panel is diagnostic for unbalanced translocations, obviating the need for invasive testing when ultrasound markers are present.**\n- **Evaluation:** This is incorrect. Even expanded cfDNA panels that screen for microdeletions/duplications are still *screening* tests, not diagnostic tests. They have inherent limitations in sensitivity and specificity and cannot resolve the complete nature of a complex rearrangement. Given major structural anomalies on ultrasound, diagnostic testing via an invasive procedure is necessary for a definitive diagnosis.\n- **Verdict:** **Incorrect**.\n\n**D. Chromosomal microarray analysis on amniotic fluid suffices in suspected translocation; parental studies are not needed if microarray identifies a copy-number variant.**\n- **Evaluation:** This is incorrect. While CMA is essential, it does not suffice on its own. A karyotype is typically performed concurrently to characterize the structure of the rearrangement. Critically, the claim that parental studies are not needed is false. Determining whether the translocation is inherited or de novo is essential for accurate genetic counseling about recurrence risk, especially with the given family history.\n- **Verdict:** **Incorrect**.\n\n**E. Chorionic villus sampling cannot identify translocations and is contraindicated when a structural chromosomal abnormality is suspected.**\n- **Evaluation:** This statement is factually incorrect. Chorionic villus sampling (CVS) obtains placental tissue from which both karyotype and CMA can be performed, and it can readily identify translocations. While amniocentesis is generally the preferred procedure in the second trimester (the patient is at $20$ weeks) to avoid potential confusion from confined placental mosaicism, CVS is not absolutely contraindicated and is certainly not incapable of detecting translocations.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "5074419"}]}